6533b873fe1ef96bd12d58f1
RESEARCH PRODUCT
Role of Circulating miRNAs as Biomarkers in Idiopathic Pulmonary Arterial Hypertension: Possible Relevance of miR-23a
Manuel Mata-roigCarmen CardaLara MilianJulio Cortijo GimenoGustavo JuanIrene SarrionIdelfonso FurestMercedes Ramonsubject
AdultMaleAgingArticle SubjectNF-E2-Related Factor 2Idiopathic Pulmonary HypertensionBiologyBiochemistryPulmonary function testingmicroRNAmedicineGene silencingHumansFamilial Primary Pulmonary Hypertensionlcsh:QH573-671Cells CulturedAgedlcsh:CytologySuperoxide DismutaseGene Expression ProfilingCytochromes cCell BiologyGeneral MedicineMiddle Agedmedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaGene expression profilingMicroRNAsmedicine.anatomical_structureHeart failureImmunologyVascular resistanceBiomarker (medicine)FemaleBiomarkersHeme Oxygenase-1Research ArticleTranscription Factorsdescription
Idiopathic pulmonary hypertension (IPAH) is a rare disease characterized by a progressive increase in pulmonary vascular resistance leading to heart failure. MicroRNAs (miRNAs) are small noncoding RNAs that control the expression of genes, including some involved in the progression of IPAH, as studied in animals and lung tissue. These molecules circulate freely in the blood and their expression is associated with the progression of different vascular pathologies. Here, we studied the expression profile of circulating miRNAs in 12 well-characterized IPAH patients using microarrays. We found significant changes in 61 miRNAs, of which the expression of miR23a was correlated with the patients’ pulmonary function. We also studied the expression profile of circulating messenger RNA (mRNAs) and found that miR23a controlled 17% of the significantly changed mRNA, including PGC1α, which was recently associated with the progression of IPAH. Finally we found that silencing of miR23a resulted in an increase of the expression of PGC1α, as well as in its well-known regulated genesCYC,SOD,NRF2, andHO1. The results point to the utility of circulating miRNA expression as a biomarker of disease progression.
year | journal | country | edition | language |
---|---|---|---|---|
2015-02-01 | Oxidative Medicine and Cellular Longevity |